{
    "ticker": "VRPX",
    "name": "Verrica Pharmaceuticals Inc.",
    "description": "Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for dermatological conditions. Founded in 2017 and headquartered in West Chester, Pennsylvania, Verrica's primary aim is to address significant unmet needs in patients suffering from skin disorders. The company's lead product candidate, VP-102, is a proprietary formulation of cantharidin, which is being developed as a topical treatment for common warts. Common warts are a prevalent condition that affects millions of people, and current treatment options are often ineffective or painful. Verrica\u2019s approach leverages its expertise in dermatology to provide a safer and more effective solution for patients. The company is committed to advancing its product pipeline through rigorous clinical trials and to bringing new therapies to market that can enhance patients' quality of life. With a strong focus on innovation and patient-centered care, Verrica aims to become a leader in the dermatology field and is well-positioned to achieve its goals as it continues to progress its clinical programs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "West Chester, Pennsylvania, USA",
    "founded": "2017",
    "website": "https://www.verricapharma.com",
    "ceo": "David P. O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/VerricaPharma",
        "linkedin": "https://www.linkedin.com/company/verrica-pharmaceuticals/"
    },
    "investor_relations": "https://ir.verricapharma.com",
    "key_executives": [
        {
            "name": "David P. O'Connor",
            "position": "CEO"
        },
        {
            "name": "Katherine A. B. G. Kearney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Dermatological Treatments",
            "products": [
                "VP-102"
            ]
        }
    ],
    "seo": {
        "meta_title": "Verrica Pharmaceuticals Inc. | Innovative Dermatological Treatments",
        "meta_description": "Discover Verrica Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on innovative treatments for skin disorders. Learn about their lead candidate VP-102 and commitment to patient care.",
        "keywords": [
            "Verrica Pharmaceuticals",
            "Dermatology",
            "Biopharmaceuticals",
            "VP-102",
            "Cantharidin",
            "Skin Conditions"
        ]
    },
    "faq": [
        {
            "question": "What does Verrica Pharmaceuticals focus on?",
            "answer": "Verrica Pharmaceuticals focuses on developing innovative treatments for dermatological conditions."
        },
        {
            "question": "What is VP-102?",
            "answer": "VP-102 is Verrica's lead product candidate, a topical treatment for common warts using a proprietary formulation of cantharidin."
        },
        {
            "question": "Where is Verrica Pharmaceuticals headquartered?",
            "answer": "Verrica Pharmaceuticals is headquartered in West Chester, Pennsylvania, USA."
        },
        {
            "question": "When was Verrica Pharmaceuticals founded?",
            "answer": "Verrica Pharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "BMY",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "ABBV",
        "MRK"
    ]
}